









Markets
/
Stocks
/
nasdaq-bhvn
/

Biohaven Ltd

BHVN

17.390USD

-0.720-3.98%

Close 10/30, 16:00（ET）Quotes delayed by 15 min

1.84BMarket Cap

LossP/E TTM



Biohaven Ltd

17.390

-0.720-3.98%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Biohaven Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Biohaven Ltd's Score

Industry at a Glance

Industry Ranking

202 / 501

Overall Ranking

356 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 18 analysts

Buy

Current Rating

46.313

Target Price

+155.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Biohaven Ltd Highlights

StrengthsRisks

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -2.33, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 87.60M shares, decreasing 13.13% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 429.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Biohaven Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.65, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -2.33, which is -34.71% below the recent high of -1.52 and -346.85% above the recent low of -10.42.

Score

Industry at a Glance

Previous score

6.65

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 202/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.89, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Biohaven Ltd is 49.50, with a high of 75.00 and a low of 19.00.

Score

Industry at a Glance

Previous score

8.89

Change

Support & Resistance

No Data

Analyst Rating

Based on 18 analysts

Buy

Current Rating

46.313

Target Price

+155.73%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Biohaven Ltd

BHVN

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 9.09, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 18.94 and the support level at 15.08, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.37

Change

1.72

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.135

Buy

RSI(14)

55.957

Neutral

STOCH(KDJ)(9,3,3)

61.405

Neutral

ATR(14)

1.249

High Vlolatility

CCI(14)

96.330

Neutral

Williams %R

31.472

Buy

TRIX(12,20)

0.602

Sell

StochRSI(14)

32.321

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

17.338

Buy

MA10

17.069

Buy

MA20

16.578

Buy

MA50

15.548

Buy

MA100

15.021

Buy

MA200

21.055

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 82.81%, representing a quarter-over-quarter decrease of 17.18%. The largest institutional shareholder is The Vanguard, holding a total of 9.23M shares, representing 8.72% of shares outstanding, with 5.18% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

1919 Investment Counsel, LLC

6.60M

+0.04%

Childs John W

6.51M

+5.71%

BlackRock Institutional Trust Company, N.A.

6.44M

+1.79%

Suvretta Capital Management, LLC

5.62M

Janus Henderson Investors

5.05M

-21.51%

State Street Investment Management (US)

3.54M

+3.38%

Coric (Vladimir)

3.18M

+0.84%

T. Rowe Price Associates, Inc.

Star Investors

3.08M

+12.40%

The Vanguard Group, Inc.

Star Investors

9.23M

+9.87%

Bellevue Asset Management AG

2.80M

+37.34%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.